Cerianna: Advancing Estrogen Receptor Targeted PET-CT for Breast Cancer Diagnosis and Beyond

Gary Ulaner , MD, PhD, FACNM discussed targeted estrogen receptor PET CT with Cerianna as a recently FDA-approved technology for identifying patients with recurrent and metastatic breast cancer that can benefit from it. They explained the mechanism of molecular imaging, where a binding agent is linked with a radioactive isotope specific to the target cancer cell to visualize breast cancer cells throughout the body in a non-invasive way. The potential applications of using estrogen receptor targeted imaging include detecting the estrogen receptor status in recurrent or metastatic lesions, assessing estrogen receptor status in lesions that may be difficult to biopsy, providing additional information when other studies are inconclusive, and helping to assess the extent of disease particularly in breast cancers that are not very metabolic active and therefore not well seen on FDG-PET.

Breast cancer is a prevalent and increasing cancer among women, necessitating accurate detection and diagnosis for effective treatment. Targeted Estrogen receptor PET CT with Cerianna is a promising technology for detecting recurrent or metastatic breast cancer. By utilizing a radioactive diagnostic agent that binds to estrogen receptors, this non-invasive imaging method allows visualization of tumors throughout the body. The recent FDA approval of Cerianna as an adjunct to biopsy in patients with recurrent or metastatic breast cancer highlights its potential in clinical practice. This technology aids in determining estrogen receptor status in challenging lesions, helps avoid unnecessary treatment changes, provides additional information in inconclusive cases, and enables personalized treatment plans for patients. Overall, Cerianna PET CT holds great promise for improving outcomes in recurrent and metastatic breast cancer by guiding targeted therapies based on individual tumor characteristics